Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-CAR088 in Relapsed or Refractory Multiple Myeloma
NCT05521802Phase 2Recruiting
- Sponsor
- AbelZeta
- Start
- Nov 2022
- Primary completion
- Jul 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of trovocabtagene autoleucel in multiple myeloma (MM), sponsored by AbelZeta. Started Nov 2022; status: recruiting.
02
Drugs
trovocabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05521802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05521802.